Tim Chiang
Stock Analyst at Capital One
(0.75)
# 3,060
Out of 4,479 analysts
17
Total ratings
37.5%
Success rate
-6.03%
Average return
Main Sectors:
Top Industries:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics | Initiates: Overweight | $6 | $2.74 | +118.98% | 1 | Apr 23, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | n/a | $34.59 | - | 3 | Oct 30, 2023 | |
| JSPR Jasper Therapeutics | Initiates: Overweight | $70 | $22.78 | +207.29% | 1 | Aug 11, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Overweight | $44 | $37.58 | +17.08% | 2 | Jul 29, 2022 | |
| KALA Kala Pharmaceuticals | Maintains: Outperform | $300 → $200 | $6.71 | +2,880.63% | 2 | Mar 30, 2022 | |
| PCRX Pacira BioSciences | Maintains: Market Perform | n/a | $22.74 | - | 2 | May 5, 2021 | |
| RPTX Repare Therapeutics | Initiates: Outperform | n/a | $3.24 | - | 1 | Oct 28, 2020 | |
| VRCA Verrica Pharmaceuticals | Initiates: Outperform | n/a | $7.47 | - | 1 | Jun 24, 2020 | |
| TEVA Teva Pharmaceutical | Upgrades: Neutral | n/a | $16.55 | - | 3 | Sep 17, 2018 | |
| SMMT Summit Therapeutics | Initiates: Buy | n/a | $7.54 | - | 1 | Feb 13, 2018 |
Heron Therapeutics
Apr 23, 2024
Initiates: Overweight
Price Target: $6
Current: $2.74
Upside: +118.98%
Protagonist Therapeutics
Oct 30, 2023
Initiates: Overweight
Price Target: n/a
Current: $34.59
Upside: -
Jasper Therapeutics
Aug 11, 2023
Initiates: Overweight
Price Target: $70
Current: $22.78
Upside: +207.29%
Amphastar Pharmaceuticals
Jul 29, 2022
Initiates: Overweight
Price Target: $44
Current: $37.58
Upside: +17.08%
Kala Pharmaceuticals
Mar 30, 2022
Maintains: Outperform
Price Target: $300 → $200
Current: $6.71
Upside: +2,880.63%
Pacira BioSciences
May 5, 2021
Maintains: Market Perform
Price Target: n/a
Current: $22.74
Upside: -
Repare Therapeutics
Oct 28, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.24
Upside: -
Verrica Pharmaceuticals
Jun 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $7.47
Upside: -
Teva Pharmaceutical
Sep 17, 2018
Upgrades: Neutral
Price Target: n/a
Current: $16.55
Upside: -
Summit Therapeutics
Feb 13, 2018
Initiates: Buy
Price Target: n/a
Current: $7.54
Upside: -